61874-04-2 Usage
General Description
4-HYDROXY-3-CARBOXALDEHYDEACETIC ACID METHYL ESTER is a chemical compound with the molecular formula C9H10O4. It is an ester derivative of 4-HYDROXY-3-CARBOXALDEHYDEACETIC ACID, which is a naturally occurring compound found in various plant species. This chemical is commonly used in the fragrance and flavor industry, as well as in the synthesis of pharmaceuticals and agricultural products. It is known for its sweet, fruity aroma and is used as a flavoring agent in food and beverages. Additionally, it has demonstrated antioxidant and anti-inflammatory properties, making it a potential candidate for medicinal applications.
Check Digit Verification of cas no
The CAS Registry Mumber 61874-04-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,8,7 and 4 respectively; the second part has 2 digits, 0 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 61874-04:
(7*6)+(6*1)+(5*8)+(4*7)+(3*4)+(2*0)+(1*4)=132
132 % 10 = 2
So 61874-04-2 is a valid CAS Registry Number.
InChI:InChI=1/C10H10O4/c1-14-10(13)5-7-2-3-9(12)8(4-7)6-11/h2-4,6,12H,5H2,1H3
61874-04-2Relevant articles and documents
MITOCHONDRIA-TARGETED ISOKETAL/ISOLEVUGLANDIN SCAVENGERS AND USES THEREOF
-
Paragraph 0062, (2021/08/06)
The use of novel 2-hydroxybenzylamine derivatives as scavengers of isolevuglandins.
NEW COMPOUNDS AND USES THEREOF FOR DETECTION OF TARGET MOLECULES IN A SAMPLE
-
Page/Page column 46; 47, (2018/04/27)
The present invention relates to new profluorophores and conjugates thereof and their use for the detection of target molecule in a sample, in particular nucleic acid target molecules. The invention relates to new profluorophores and new fluorophores and methods of use thereof particularly useful in the fields of diagnostics and quality control.
FACTOR VIIA INHIBITOR
-
Paragraph 0176, (2014/04/03)
The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.